One thing I find interesting about @bioprotocol is how it moves longevity into the clinic through @DogYearsDAO. Senior dogs face OA, inflammation, and muscle loss like humans; follistatin gene therapy targets myostatin/activin to boost mobility and reduce pain while trials run via local vets with consent and data verified on‑chain Roadmap: token launch Q3 2025, pilot Q4 2025 on 50 100 dogs, then decentralized expansion through 2026 2027. With $BIO tying participation to value via veBIO/BioXP, the $18B pet pharma market becomes a proving ground for mammalian longevity
4.14K
42
The content on this page is provided by third parties. Unless otherwise stated, OKX is not the author of the cited article(s) and does not claim any copyright in the materials. The content is provided for informational purposes only and does not represent the views of OKX. It is not intended to be an endorsement of any kind and should not be considered investment advice or a solicitation to buy or sell digital assets. To the extent generative AI is utilized to provide summaries or other information, such AI generated content may be inaccurate or inconsistent. Please read the linked article for more details and information. OKX is not responsible for content hosted on third party sites. Digital asset holdings, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition.